PHILADELPHIA — New drugs that inhibit B-cell receptor signaling pathways can be an effective treatment for B-cell malignancies, according to a speaker here.
“B-cell receptor signaling is also crucial for survival and growth of malignant B cells. Leukemias and lymphomas rely on this pathway for their growth. I want to emphasize that there is a family of drugs that can inhibit Bruton’s tyrosine kinase. The most well known is ibrutinib,” Arman Mashayekhi, MD, said at the Wills Eye Conference.
Traditional treatments for vitreoretinal lymphomas include external beam